Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference

Reuters

03/03

Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will present one oral and two poster sessions at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Copenhagen, held in-person and online March 17-21, 2026, showcasing new data on enhanced brain delivery of sabirnetug, sabirnetug biomarker treatment responses, and new amyloid beta oligomer-targeting antibodies. Event-related materials: https://www.globenewswire.com/Tracker?data=vC5S76bf6EVdiMsTYm3IGywLE-0tGPxq2KsimNj7ovgoYx5h3S0-ZfArUXv_aerJ6pEcU_bmHh2ggdVJCkCGjg_HO-u9tDICYpRJA-yNRcM= and the July 2025 collaboration announcement link https://www.globenewswire.com/Tracker?data=SgDD5Hkz0NkBuEH5Rlps0Q3tR3OxNamB6mEBvyQqnLQAUui2ycGEJxqxTU7Ed8SrseuZSahxLt2HFZ6Ptc5hXh2HSIFjnLCYT-t8faXGEJbQYqhItA9o-jrl1Q_fe7tyLdOUAPtwt7hED1ZHFdXAuPIRfi-0mvM6HlKDE9O48vtcWJ3EFMPJZbgNkY1BvMMBBqPpG25D400S52ejfoVe0Sx45XMKo3QL2mCqOzGG5DA=.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603030800PRIMZONEFULLFEED9664542) on March 03, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2616340078"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616340078\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616340078?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616340078","market":"nz","top_or_hot":-1,"title":"Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ABOS\">Acumen Pharmaceuticals, Inc.</a> (NASDAQ: ABOS) will present one oral and two poster sessions at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Copenhagen, held in-person and online March 17-21, 2026, showcasing new data on enhanced brain delivery of sabirnetug, sabirnetug biomarker treatment responses, and new amyloid beta oligomer-targeting antibodies. Event-related materials: https://www.globenewswire.com/Tracker?data=vC5S76bf6EVdiMsTYm3IGywLE-0tGPxq2KsimNj7ovgoYx5h3S0-ZfArUXv_aerJ6pEcU_bmHh2ggdVJCkCGjg_HO-u9tDICYpRJA-yNRcM= and the July 2025 collaboration announcement link https://www.globenewswire.com/Tracker?data=SgDD5Hkz0NkBuEH5Rlps0Q3tR3OxNamB6mEBvyQqnLQAUui2ycGEJxqxTU7Ed8SrseuZSahxLt2HFZ6Ptc5hXh2HSIFjnLCYT-t8faXGEJbQYqhItA9o-jrl1Q_fe7tyLdOUAPtwt7hED1ZHFdXAuPIRfi-0mvM6HlKDE9O48vtcWJ3EFMPJZbgNkY1BvMMBBqPpG25D400S52ejfoVe0Sx45XMKo3QL2mCqOzGG5DA=.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603030800PRIMZONEFULLFEED9664542) on March 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-03-03 21:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ABOS\">Acumen Pharmaceuticals, Inc.</a> (NASDAQ: ABOS) will present one oral and two poster sessions at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Copenhagen, held in-person and online March 17-21, 2026, showcasing new data on enhanced brain delivery of sabirnetug, sabirnetug biomarker treatment responses, and new amyloid beta oligomer-targeting antibodies. Event-related materials: https://www.globenewswire.com/Tracker?data=vC5S76bf6EVdiMsTYm3IGywLE-0tGPxq2KsimNj7ovgoYx5h3S0-ZfArUXv_aerJ6pEcU_bmHh2ggdVJCkCGjg_HO-u9tDICYpRJA-yNRcM= and the July 2025 collaboration announcement link https://www.globenewswire.com/Tracker?data=SgDD5Hkz0NkBuEH5Rlps0Q3tR3OxNamB6mEBvyQqnLQAUui2ycGEJxqxTU7Ed8SrseuZSahxLt2HFZ6Ptc5hXh2HSIFjnLCYT-t8faXGEJbQYqhItA9o-jrl1Q_fe7tyLdOUAPtwt7hED1ZHFdXAuPIRfi-0mvM6HlKDE9O48vtcWJ3EFMPJZbgNkY1BvMMBBqPpG25D400S52ejfoVe0Sx45XMKo3QL2mCqOzGG5DA=.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603030800PRIMZONEFULLFEED9664542) on March 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"納斯達克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL7tNLWQ:1","article_id":"2616340078","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616340078","pubTimestamp":1772542862,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference               Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will present one oral and two poster sessions at the","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","EVT.AU":"EVT Ltd","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4539":"次新股","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","ABOS":"Acumen Pharmaceuticals, Inc.","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","BK7035":"电影和娱乐"},"translate_title":"Acumen Pharmaceuticals将在AD/PD 2026会议上展示阿尔茨海默病治疗进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVT.AU":0.9,"NDAQ":0.9,"ABOS":0.9},"content_text":"Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference\n    \n\nAcumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will present one oral and two poster sessions at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Copenhagen, held in-person and online March 17-21, 2026, showcasing new data on enhanced brain delivery of sabirnetug, sabirnetug biomarker treatment responses, and new amyloid beta oligomer-targeting antibodies. Event-related materials: https://www.globenewswire.com/Tracker?data=vC5S76bf6EVdiMsTYm3IGywLE-0tGPxq2KsimNj7ovgoYx5h3S0-ZfArUXv_aerJ6pEcU_bmHh2ggdVJCkCGjg_HO-u9tDICYpRJA-yNRcM= and the July 2025 collaboration announcement link https://www.globenewswire.com/Tracker?data=SgDD5Hkz0NkBuEH5Rlps0Q3tR3OxNamB6mEBvyQqnLQAUui2ycGEJxqxTU7Ed8SrseuZSahxLt2HFZ6Ptc5hXh2HSIFjnLCYT-t8faXGEJbQYqhItA9o-jrl1Q_fe7tyLdOUAPtwt7hED1ZHFdXAuPIRfi-0mvM6HlKDE9O48vtcWJ3EFMPJZbgNkY1BvMMBBqPpG25D400S52ejfoVe0Sx45XMKo3QL2mCqOzGG5DA=.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603030800PRIMZONEFULLFEED9664542) on March 03, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}